JAK2 and myeloproliferative disorder: Epigenetic silencing of SOCS1 and SOCS3 genes was observed in patients and murine models of chronic myeloproliferative disorders and AML expressing JAK2(V617F) mutation (Cooper et al., 2010), suggesting that JAK/STAT contributes to growth factor hypersensitivity induced by JAK2 mutations.